1
|
Zhang S, Qin YP, Kuang JM, Liu YH. Proteomic investigation of resistance to chemotherapy drugs in osteosarcoma. Technol Health Care 2018; 26:145-153. [DOI: 10.3233/thc-171038] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Shuang Zhang
- College of Computer Science, Neijiang Normal University, Neijiang, Sichuan, China
- The Engineering & Technical College of Chengdu University of Technology, Leshan, Sichuan, China
- College of Computer Science, Neijiang Normal University, Neijiang, Sichuan, China
| | - Yu-Ping Qin
- College of Computer Science, Neijiang Normal University, Neijiang, Sichuan, China
- The Engineering & Technical College of Chengdu University of Technology, Leshan, Sichuan, China
- College of Computer Science, Neijiang Normal University, Neijiang, Sichuan, China
| | - Jiang-Ming Kuang
- College of Computer Science, Neijiang Normal University, Neijiang, Sichuan, China
- The Engineering & Technical College of Chengdu University of Technology, Leshan, Sichuan, China
| | - Yi-He Liu
- College of Computer Science, Neijiang Normal University, Neijiang, Sichuan, China
- College of Computer Science, Neijiang Normal University, Neijiang, Sichuan, China
| |
Collapse
|
2
|
Wu H, Chen S, Yu J, Li Y, Zhang XY, Yang L, Zhang H, Hou Q, Jiang M, Brunicardi FC, Wang C, Wu S. Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells. Cancer Lett 2018; 420:156-167. [PMID: 29410067 DOI: 10.1016/j.canlet.2018.01.059] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2017] [Revised: 01/23/2018] [Accepted: 01/24/2018] [Indexed: 02/07/2023]
Abstract
Paclitaxel is widely used in the combination chemotherapy for many cancers including esophageal squamous cell carcinoma (ESCC). However, the paclitaxel resistance occurs frequently in treating ESCC and the mechanism is not fully understood yet. The heterogeneity of gene expression within the drug-resistant cancer cells may be one of the major factors contributing to its resistance. In the present study, we successfully induced paclitaxel resistance in ESCC cell line KYSE-30 through low dose and long-term treatment of paclitaxel. Gene expression profiles were measured utilizing population RNA-seq and single-cell RNA-seq (scRNA-seq). 37 single cells from KYSE-30 cells and 73 single cells from paclitaxel resistant KYSE-30 cells (Taxol-R) were subjected to scRNA-seq. Weighted gene co-expression network analysis (WGCNA) of scRNA-seq data revealed two major subpopulations in both KYSE-30 and Taxol-R cancer cells. Two subpopulations based on the KRT19 expression levels in KYSE-30 cells exhibited different paclitaxel sensitivity, suggesting the existence of an intrinsic paclitaxel resistance in KYSE-30 cells. In addition, the Taxol-R cells that acquired the resistance to paclitaxel through induction were characterized with higher expressions of proteasomes but a lower expression of HIF-1 signaling genes. Furthermore, we showed that carfilzomib (CFZ), a proteasome inhibitor, could attenuate the paclitaxel resistance in Taxol-R cancer cells through activating the HIF-1 signaling. Our new finding may pave a way leading to an improvement in the treatment on cancers including ESCC by combining CFZ with paclitaxel as a novel approach for cancer therapy.
Collapse
Affiliation(s)
- Hongjin Wu
- Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, 320000, Zhejiang Province, PR China; Center for Genomics & Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA; Department of Life Science, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul 121-742, Republic of Korea
| | - Sean Chen
- Center for Genomics & Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA
| | - Juehua Yu
- Department of Surgery, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, 43614, USA
| | - Ying Li
- Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, 320000, Zhejiang Province, PR China
| | - Xiao-Yan Zhang
- Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, 320000, Zhejiang Province, PR China
| | - Ling Yang
- Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, 320000, Zhejiang Province, PR China
| | - Hongfang Zhang
- Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, 320000, Zhejiang Province, PR China
| | - Qiang Hou
- Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, 320000, Zhejiang Province, PR China
| | - Mingfeng Jiang
- Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, 320000, Zhejiang Province, PR China
| | - F Charles Brunicardi
- Department of Surgery, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, 43614, USA.
| | - Charles Wang
- Center for Genomics & Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
| | - Shixiu Wu
- Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, 320000, Zhejiang Province, PR China.
| |
Collapse
|
3
|
Yang JZ, Ma SR, Rong XL, Zhu MJ, Ji QY, Meng LJ, Gao YY, Yang YD, Wang Y. Characterization of multidrug-resistant osteosarcoma sublines and the molecular mechanisms of resistance. Mol Med Rep 2016; 14:3269-76. [DOI: 10.3892/mmr.2016.5590] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Accepted: 07/08/2016] [Indexed: 11/06/2022] Open
|
4
|
Askarian-Amiri ME, Leung E, Finlay G, Baguley BC. The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance. Methods Mol Biol 2016; 1395:207-27. [PMID: 26910076 DOI: 10.1007/978-1-4939-3347-1_12] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Recent genomic and transcriptomic analysis has revealed that the majority of the human genome is transcribed as nonprotein-coding RNA. These transcripts, known as long noncoding RNA, have structures similar to those of mRNA. Many of these transcripts are now thought to have regulatory roles in different biological pathways which provide cells with an additional layer of regulatory complexity in gene expression and proteome function in response to stimuli. A wide variety of cellular functions may thus depend on the fine-tuning of interactions between noncoding RNAs and other key molecules in cell signaling networks. Deregulation of many noncoding RNAs is thought to occur in a variety of human diseases, including neoplasia and cancer drug resistance. Here we discuss recent findings on the molecular functions of long noncoding RNAs in cellular pathways mediating resistance to anticancer drugs.
Collapse
Affiliation(s)
- Marjan E Askarian-Amiri
- Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand. .,Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
| | - Euphemia Leung
- Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.,Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Graeme Finlay
- Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.,Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Bruce C Baguley
- Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand
| |
Collapse
|
5
|
Chen YJ, Kuo CD, Chen SH, Chen WJ, Huang WC, Chao KSC, Liao HF. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells. PLoS One 2012; 7:e37006. [PMID: 22615870 PMCID: PMC3352857 DOI: 10.1371/journal.pone.0037006] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2011] [Accepted: 04/11/2012] [Indexed: 11/18/2022] Open
Abstract
Multi-drug resistance (MDR), an unfavorable factor compromising treatment efficacy of anticancer drugs, involves upregulated ATP binding cassette (ABC) transporters and activated Sonic hedgehog (Shh) signaling. By preparing human breast cancer MCF-7 cells resistant to doxorubicin (DOX), we examined the effect and mechanism of norcantharidin (NCTD), a small-molecule synthetic compound, on reversing multidrug resistance. The DOX-prepared MCF-7R cells also possessed resistance to vinorelbine, characteristic of MDR. At suboptimal concentration, NCTD significantly inhibited the viability of DOX-sensitive (MCF-7S) and DOX-resistant (MCF-7R) cells and reversed the resistance to DOX and vinorelbine. NCTD increased the intracellular accumulation of DOX in MCF-7R cells and suppressed the upregulated the mdr-1 mRNA, P-gp and BCRP protein expression, but not the MRP-1. The role of P-gp was strengthened by partial reversal of the DOX and vinorelbine resistance by cyclosporine A. NCTD treatment suppressed the upregulation of Shh expression and nuclear translocation of Gli-1, a hallmark of Shh signaling activation in the resistant clone. Furthermore, the Shh ligand upregulated the expression of P-gp and attenuated the growth inhibitory effect of NCTD. The knockdown of mdr-1 mRNA had not altered the expression of Shh and Smoothened in both MCF-7S and MCF-7R cells. This indicates that the role of Shh signaling in MDR might be upstream to mdr-1/P-gp, and similar effect was shown in breast cancer MDA-MB-231 and BT-474 cells. This study demonstrated that NCTD may overcome multidrug resistance through inhibiting Shh signaling and expression of its downstream mdr-1/P-gp expression in human breast cancer cells.
Collapse
Affiliation(s)
- Yu-Jen Chen
- Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan
- Institute of Traditional Medicine, National Yang Ming University, Taipei, Taiwan
| | - Cheng-Deng Kuo
- Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Szu-Han Chen
- Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan
| | - Wei-Jen Chen
- Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan
| | - Wen-Chien Huang
- Division of Thoracic Surgery, Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan
| | - K. S. Clifford Chao
- Department of Radiation Oncology, Columbia University, New York, New York, United States of America
| | - Hui-Fen Liao
- Institute of Traditional Medicine, National Yang Ming University, Taipei, Taiwan
- Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
- Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan
- * E-mail:
| |
Collapse
|
6
|
Dalla-Torre CA, de Toledo SRC, Yoshimoto M, Petrilli AS, Andrade JAD, Chilton-MacNeill S, Squire JA, Zielenska M. Expression of major vault protein gene in osteosarcoma patients. J Orthop Res 2007; 25:958-63. [PMID: 17415755 DOI: 10.1002/jor.20371] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Osteosarcoma (OS) is a primary malignant tumor of bone. Despite the successful use of multiple chemotherapeutic agents in the treatment of OS, more than 30% of OS tumors remain resistant to treatment. Elucidation of cellular resistance mechanisms may lead to better treatments for cancer patients. In this study, we used the low-density expression cDNA array, GEArray Q Series Human Cancer Drug Resistance and Metabolism Gene Array to screen genes related to drug resistance in 15 OS tumors. Expression patterns of the MPV gene were validated by real time PCR on 45 OS patient tumor samples and correlated with clinical and pathological data. Major vault protein (MVP) expression was present in 24 (53%) tumor samples and absent in 21 (47%). Samples from surgery showed correlation between the expression of MVP, metastatic disease at diagnosis and event free survival (EFS). The MVP gene expression correlates with metastatic disease at diagnosis after neoadjuvant chemotherapy (p=0.048), and is also associated with worse EFS (p=0.036). These findings suggest that MVP expression is involved in one of the mechanisms of drug resistance in OS and is induced by chemotherapy.
Collapse
Affiliation(s)
- Cristiane Arruda Dalla-Torre
- Department of Pediatrics, Instituto de Oncologia Pediátrica, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil, and Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
Our understanding of the clinical and cellular pharmacology of drugs commonly used in the treatment of childhood cancer have increased greatly over the past two decades. However, with the exception of childhood acute lymphoblastic leukaemia (ALL), our current knowledge of factors such as inter-patient pharmacokinetic variability and cellular determinants of chemosensitivity has not been utilized in the design of integrated clinical studies. Recent pre-clinical and clinical evaluation of the topoisomerase I inhibitors topotecan and irinotecan has highlighted the potential importance of pharmacological factors in their effectiveness as cytotoxics. In this review, the clinical and cellular pharmacology of vincristine, actinomycin D, doxorubicin, cyclophosphamide, ifosfamide, cisplatin, carboplatin and etoposide will be discussed in relation to the major paediatric solid tumours. For each disease type, knowledge of the clinical and cellular pharmacology of a candidate drug will be related to pharmacodynamic responses such as response, toxicity and prognosis. For diseases such as Wilms' tumour, osteogenic sarcoma and Ewing's tumour, histological response to initial induction chemotherapy is of prognostic significance, and the depth of response is increasingly recognised as an important determinant of prognosis for high-risk neuroblastoma. For several of these tumour types, the dose-intensity of chemotherapy may be an important variable in determining prognosis. However the relationship between pharmacokinetic variability, cellular pharmacology and the major determinants of chemosensitivity to those drugs employed in first line therapy is unknown. The study of these relationships, by means of up front window studies in children who present with high-risk disease, may be as important as the introduction of new agents. Indeed, the optimisation of current therapies may be required to allow a fully informed selection of those children for whom novel therapies are truly needed. Funding and international collaboration at the clinical and scientific level would be required to achieve these aims.
Collapse
Affiliation(s)
- E J Estlin
- Department of Paediatric Oncology, Royal Manchester Children's Hospital, Pendlebury, Manchester, M27 4HA, UK.
| | | |
Collapse
|